樂觀
$180.85
情境價格
$126.550
-1.531 (-1.21%)收盤時
AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.
Aptargroup Inc is a good buy right now due to its current price of $126.55, which is below the average analyst price target of $150, indicating significant upside potential. The forward P/E ratio of 19.76 suggests the stock is reasonably valued compared to its expected earnings growth. Additionally, the RSI of 66.28 indicates that the stock is approaching overbought territory, but it is not yet excessively overbought, allowing for potential further gains. The main risk is the recent price decline below the 200-day moving average, which could signal a bearish trend if it continues, as seen in the recent news about market caution.
UBS
$135
2026-10-09
UBS
2026-10-09
目標價
$135
BofA
$154
2026-10-06
BofA
2026-10-06
目標價
$154
BofA
$172
2026-07-31
BofA
2026-07-31
目標價
$172
Raymond James
$160
2026-07-15
Raymond James
2026-07-15
目標價
$160
BofA
$173
2026-07-14
BofA
2026-07-14
目標價
$173
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Aptar Appoints Virginie Maes as President of Pharma Business

Aptar Pharma Secures CE Mark for LuerVax® Device

Latest Wall Street Rating Updates

Aptar Partners with MGH to Advance Nose-to-Brain Drug Delivery

AptarGroup Shares Fall Below 200-Day Moving Average
AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets. It operates in the Basic Materials sector (PLASTICS PRODUCTS, NEC industry).
Aptargroup Inc is a good buy right now due to its current price of $126.55, which is below the average analyst price target of $150, indicating significant upside potential. The forward P/E ratio of 19.76 suggests the stock is reasonably valued compared to its expected earnings growth. Additionally, the RSI of 66.28 indicates that the stock is approaching overbought territory, but it is not yet excessively overbought, allowing for potential further gains. The main risk is the recent price decline below the 200-day moving average, which could signal a bearish trend if it continues, as seen in the recent news about market caution.
9 analysts cover ATR: 2 rate it Buy, 6 Hold and 1 Sell. The average price target is 145.33.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。